nach oben

Erschienen in:

01.01.2011 | Original Article

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates

verfasst von: Minoru Miyashita, Takanori Ishida, Kazuyuki Ishida, Kentaro Tamaki, Masakazu Amari, Mika Watanabe, Noriaki Ohuchi, Hironobu Sasano

Erschienen in: Virchows Archiv | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

We attempted to subclassify triple negative breast cancer (TNBC) cases into subgroups according to clinical outcome or prognosis of TNBC patients using archival specimens. We analyzed 102 Japanese cases of invasive TNBC who underwent surgery between January 1998 and December 2007. The clinicopathological factors and clinical information were retrospectively retrieved from reviewing the charts of the patients. Immunohistochemical staining was performed for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor 1 (EGFR1), CK5/6, CK14, Ki-67, and CD31 for microvessel density (MVD). Median follow-up time of the patients was 68.5 months. Multivariable analysis demonstrated that pathologic node status was the most significantly associated with relapse-free survival (RFS) and breast cancer-specific survival (BCSS) of these patients. Pathological tumor size, basal-like type, Ki-67 labeling index (LI) and MVD were also independently associated with RFS and BCSS. Based on these results, we devised the risk score system reflecting hazard ratios of these prognostic factors above. With this system, TNBC patients in this study were classified into three subgroups (low-risk group: score 0–3, intermediate-risk group: score 4–7 and high-risk group: score 8–10). The significant difference of RFS and BCSS was detected among these three different subgroups of the patients (p < 0.05). We propose the risk score system, which incorporated pathologic nodal status, size of the primary tumor, the presence or absence of basal-like features, Ki-67 LI, and MVD in order to predict postoperative clinical course of the Japanese TNBC patients.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumors. Nature 406:747–752CrossRefPubMed

Sorlie T, Perou C, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874CrossRefPubMed

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374CrossRefPubMed

Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271CrossRefPubMed

Lerma E, Peiro G, Ramo’n T et al (2007) Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2//neu (basal-like breast carcinomas). Mod Pathol 20(11):1200–1207CrossRefPubMed

Reis-Filho JS, Tutt ANJ (2008) Triple negative tumours: a critical review. Histopathology 52:108–118CrossRefPubMed

Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32CrossRefPubMed

Rakha EA, Reis-Filho JS, Ian OE (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581CrossRefPubMed

Maggie CU-C, David V, Chris B et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376CrossRef

10.

Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721–1728CrossRefPubMed

11.

Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334CrossRefPubMed

12.

Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8(1):307CrossRefPubMed

13.

Cornelia L, Chafika M, Kenneth RH et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281CrossRef

14.

Anne VS, Nadège G, Carlo L et al (2007) Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9(2):1–15CrossRef

15.

Jocelyne J, Laetitia P, Laetitia R et al (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207(3):260–268CrossRef

16.

Francois B, Pascal F, Nathalie C et al (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66(9):4636–4644CrossRef

17.

Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York, pp 131–141

18.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a larger study with long-term follow-up. Histopathology 19:403–410CrossRefPubMed

19.

Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC

20.

Wolff AC, Hammond MH, Schwartz JN et al (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed

21.

Spyratos F, Ferrero-PM TM et al (2002) Correlation between MIB-1 and other proliferation marker clinical implications of the MIB-1 cutoff value. Cancer 94(8):2151–2159CrossRefPubMed

22.

Attiqa N, Nadeem Q, Georges V et al (2002) Prognostic factors in node-negative breast cancer a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235:10–26CrossRef

23.

Ander U, Ian ES, Mitch D (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220CrossRef

24.

Azambuja E, Cardoso F, Castro G et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 96:1504–1513CrossRefPubMed

25.

Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324:1–8CrossRefPubMed

26.

Weidner N, Folkman J, Pozza F et al (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887CrossRefPubMed

27.

Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102(17):2031–2037PubMed

28.

Matthew JE, Yu T, Jingqin L et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388CrossRef

29.

Wang S, Yang H, Tong F et al (2009) Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho 36(2):255–258PubMed

30.

Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8):1168–1176CrossRefPubMed

31.

Edith A, Perez A, Aubrey T et al (2010) Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat 120:285–291CrossRef

32.

Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434(7035):913–917CrossRefPubMed

33.

Ratnam K, Low JA (2007) Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13(5):1383–1388CrossRefPubMed

34.

Yamamoto Y, Toi M, Kondo S et al (1996) Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2:821–826PubMed

35.

Adams J, Carder PJ, Downey S et al (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60:2898–2905PubMed

36.

Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407–5414PubMed

37.

Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20(10):1639–1646CrossRefPubMed

38.

Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676CrossRefPubMed

39.

Ryan PD, Tung NM, Isakoff SJ et al (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 27 (Suppl). (Abstr 551)

40.

Steinbjørn H, Dorthe AG, Flemming BS et al (2000) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6:139–146

41.

Bernard U, Patrick N, Michel C et al (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64:2941–2955CrossRef

42.

Mohammed RAA, Green A, El-Shikh S et al (2007) Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96:1092–1100CrossRefPubMed

43.

Rabab A, Ian O, Somaia E et al (2009) Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat 113:261–273CrossRef

44.

Nair L, Barbara S, Daniella V et al (2009) Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology 55:594–599CrossRef

45.

Nieto Y, Woods J, Nawaz F et al (2007) Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 97:391–397CrossRefPubMed

46.

Acenero MJ, Gonzalez JF, Gallego MG et al (1998) Vascular enumeration as a significant prognosticator for invasive breast carcinoma. J Clin Oncol 16:1684–1688PubMed

47.

Ana B, Pilar E, Rosa Z et al (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206–215CrossRef

Titel: Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates
verfasst von: Minoru Miyashita
Takanori Ishida
Kazuyuki Ishida
Kentaro Tamaki
Masakazu Amari
Mika Watanabe
Noriaki Ohuchi
Hironobu Sasano
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 1/2011
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-010-1009-2

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates

Abstract

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis

Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations

Immunophenotypic predictive profiling of BRCA1-associated breast cancer

Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome

Promoter CpG island hypermethylation during breast cancer progression

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren